X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Strides Arcolab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs STRIDES SHASUN LTD - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS STRIDES SHASUN LTD NOVARTIS/
STRIDES SHASUN LTD
 
P/E (TTM) x 299.3 38.6 775.5% View Chart
P/BV x 33.2 1.0 3,459.6% View Chart
Dividend Yield % 1.4 1.0 133.5%  

Financials

 NOVARTIS   STRIDES SHASUN LTD
EQUITY SHARE DATA
    NOVARTIS
Mar-18
STRIDES SHASUN LTD
Mar-17
NOVARTIS/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs7581,275 59.5%   
Low Rs579918 63.1%   
Sales per share (Unadj.) Rs228.4389.6 58.6%  
Earnings per share (Unadj.) Rs31.728.0 113.5%  
Cash flow per share (Unadj.) Rs32.848.9 67.0%  
Dividends per share (Unadj.) Rs10.004.50 222.2%  
Dividend yield (eoy) %1.50.4 364.4%  
Book value per share (Unadj.) Rs297.1303.1 98.0%  
Shares outstanding (eoy) m24.6989.42 27.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.92.8 104.0%   
Avg P/E ratio x21.139.2 53.7%  
P/CF ratio (eoy) x20.422.4 91.0%  
Price / Book Value ratio x2.23.6 62.2%  
Dividend payout %31.516.1 195.8%   
Avg Mkt Cap Rs m16,50598,036 16.8%   
No. of employees `0000.75.8 11.5%   
Total wages/salary Rs m1,4455,881 24.6%   
Avg. sales/employee Rs Th8,441.36,005.9 140.6%   
Avg. wages/employee Rs Th2,163.61,014.0 213.4%   
Avg. net profit/employee Rs Th1,173.1431.2 272.1%   
INCOME DATA
Net Sales Rs m5,63934,834 16.2%  
Other income Rs m1,7181,686 101.9%   
Total revenues Rs m7,35736,520 20.1%   
Gross profit Rs m-636,428 -1.0%  
Depreciation Rs m251,872 1.4%   
Interest Rs m552,269 2.4%   
Profit before tax Rs m1,5753,973 39.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m04 0.0%   
Extraordinary Inc (Exp) Rs m0-1,006 0.0%   
Tax Rs m792470 168.4%   
Profit after tax Rs m7842,501 31.3%  
Gross profit margin %-1.118.5 -6.0%  
Effective tax rate %50.311.8 424.8%   
Net profit margin %13.97.2 193.6%  
BALANCE SHEET DATA
Current assets Rs m9,52238,165 24.9%   
Current liabilities Rs m3,29630,402 10.8%   
Net working cap to sales %110.422.3 495.4%  
Current ratio x2.91.3 230.1%  
Inventory Days Days3777 47.3%  
Debtors Days Days28104 27.2%  
Net fixed assets Rs m4637,639 0.1%   
Share capital Rs m123894 13.8%   
"Free" reserves Rs m7,21326,210 27.5%   
Net worth Rs m7,33627,105 27.1%   
Long term debt Rs m016,377 0.0%   
Total assets Rs m11,10581,168 13.7%  
Interest coverage x29.52.8 1,071.9%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.50.4 118.3%   
Return on assets %7.65.9 128.5%  
Return on equity %10.79.2 115.8%  
Return on capital %22.212.1 184.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6113,465 0.5%   
Fx outflow Rs m3,6304,076 89.1%   
Net fx Rs m-3,5709,389 -38.0%   
CASH FLOW
From Operations Rs m1,6102,881 55.9%  
From Investments Rs m687-7,051 -9.7%  
From Financial Activity Rs m-2,6773,382 -79.1%  
Net Cashflow Rs m-380-788 48.2%  

Share Holding

Indian Promoters % 0.0 27.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 37.8 5.3%  
FIIs % 1.6 8.6 18.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 25.9 83.0%  
Shareholders   41,647 56,241 74.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Depreciating Rupee; IPO Buzz and Top Cues in Focus Today(Pre-Open)

Indian share markets ended lower yesterday with banking stocks and metal stocks leading the losses. At the closing bell, the BSE Sensex ended down by 188 points (0.5%).

Related Views on News

STRIDES SHASUN LTD Announces Quarterly Results (1QFY19); Net Profit Down 57.5% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, STRIDES SHASUN LTD has posted a net profit of Rs 38 m (down 57.5% YoY). Sales on the other hand came in at Rs 7 bn (down 21.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Aug 16, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS